CO39 Real-World Assessment of Efficacy and Safety of Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Systematic Review and Meta-Analysis

The efficacy and safety of natalizumab versus fingolimod for relapsing-remitting multiple sclerosis (RRMS) had conflicting results, according to data from various medical centers across the globe. Therefore, we performed a systematic review and meta-analysis of data from real-world evidence (RWE) studies to evaluate the efficacy and safety Parameters of Natalizumab Versus Fingolimod.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research